Botta, C., Barbieri, V., Ciliberto, D., Rossi, A., Rocco, D., Addeo, R., et al. (2013) Systemic Inflammatory Status at Baseline Predicts Bevacizumab Benefit in Advanced Non-Small Cell Lung Cancer Patients. Cancer Biology & Therapy, 14, 469-475.
https://doi.org/10.4161/cbt.24425

has been cited by the following article:

• TITLE: Functional Activity of Circulating Phagocytes as Potential Pretreatment Marker of Tumor Drug Resistance

  AUTHORS: Iryna V. Prokhorova, Olga V. Yurchenko, Olga N. Pyaskovskaya, Igor N. Todor, Galina I. Solyanik

  KEYWORDS: Circulating Phagocytes, Phagocytic Activity, ROS Production, Tumor Drug Resistance

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.7 No.7, July 8, 2019

  ABSTRACT: The aim of this work was a study of the functional activity of neutrophils and peripheral blood monocytes in rats with the transplanted Walker carcinosarcoma as potential predictors of the sensitivity of this tumor to doxorubicin treatment. This study provides an evidence that such indices of the functional activity of circulating phagocytes of the tumor-bearing rats as the quantity and the phagocytosis intensity of monocytes, as well as the intensity of ROS production by monocytes and neutrophils, may reflect the degree of sensitivity of the tumor to doxorubicin. So it was shown that the growth of the resistant tumor caused a significant increase of the number of circulating phagocytic cells and the intensity of phagocytosis by more than 100% (p